• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Biofilchem Share Price

    Biofil Chemicals & Pharmaceuticals Share PriceBiofil Chemicals & Pharmaceuticals

    Small Cap 3.9k Result
    ₹52.3
    -0.65 (-1.23%)
    As on 06 December, 2023 | 00:55 BSE: 524396 NSE: BIOFILCHEMISIN: INE829A01014

    Biofil Chemicals & Pharmaceuticals Performance

    Day Range

    • Low 51.60
    • High 53.05
    ₹ 52.3

    52 Week Range

    • Low 39.30
    • High 65.00
    ₹ 52.3
    • Open Price52.05
    • Previous Close52.95
    • Volume35060

    Start SIP in Biofil Chemicals & Pharmaceuticals

    Start SIP

    Biofil Chemicals & Pharmaceuticals Share Price

    • Over 1 Month 6.84%
    • Over 3 Month 5.13%
    • Over 6 Month 18.19%
    • Over 1 Year -6.94%

    Biofil Chemicals & Pharmaceuticals Key Statistics

    P/E Ratio 125.9
    PEG Ratio 6.3
    Market Cap Cr 85
    Price to Book Ratio 4.9
    EPS 0.3
    Dividend 0
    Relative Strength Index 59.07
    Money Flow Index 75.73
    MACD Signal 0.7
    Average True Range 2.31

    Biofil Chemicals & Pharmaceuticals Investment Rating

    • Master Rating:

    • Biofil Chemicals & Pharmaceuticals has an operating revenue of Rs. 34.91 Cr. on a trailing 12-month basis. An annual revenue growth of 34% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 3% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 14% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 36 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 131 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Biofil Chemicals & Pharmaceuticals Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1721413122
    Operating Expenses Qtr Cr 1721312122
    Operating Profit Qtr Cr 0000000
    Depreciation Qtr Cr 0000000
    Interest Qtr Cr 0000000
    Tax Qtr Cr 0000000
    Net Profit Qtr Cr 0000000
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 3023
    Operating Expenses Annual Cr 2921
    Operating Profit Annual in Cr 11
    Depreciation Cr 00
    Interest Annual Cr 00
    Tax Annual Cr 00
    Net Profit Annual Cr 11
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 0
    Cash from Investing Activity Annual Cr 0
    Cash from Financing Annual Activity Cr 0
    Net Cash Flow Annual Cr 0
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 1717
    Fixed Assets Annual Cr 99
    Total Non Current Assets Annual Cr 99
    Total Current Assets Annual Cr 229
    Total Assets Annual Cr 3119
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 1110
    ROE Annual % 34
    ROCE Annual % 56
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 47
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr
    Operating Expenses Qtr Cr
    Operating Profit Qtr Cr
    Depreciation Qtr Cr
    Interest Qtr Cr
    Tax Qtr Cr
    Net Profit Qtr Cr
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %
    Invest in Biofil Chemicals & Pharmaceuticals

    Biofil Chemicals & Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹52.3
    -0.65 (-1.23%)
    pointer
    • Bullish Moving Average
    • ___
    • 14
    • Bearish Moving Average
    • ___
    • 2
    • 20 Day
    • ₹50.90
    • 50 Day
    • ₹49.76
    • 100 Day
    • ₹48.76
    • 200 Day
    • ₹48.65
    • 20 Day
    • ₹50.29
    • 50 Day
    • ₹49.69
    • 100 Day
    • ₹48.43
    • 200 Day
    • ₹46.40

    Biofil Chemicals & Pharmaceuticals Resistance and Support

    PIVOT
    ₹52.32
    Resistance
    First Resistance 53.03
    Second Resistance 53.77
    Third Resistance 54.48
    RSI 59.07
    MFI 75.73
    MACD Single Line 0.70
    MACD 1.09
    Support
    First Resistance 51.58
    Second Resistance 50.87
    Third Resistance 50.13

    Biofil Chemicals & Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 39,641 2,610,360 65.85
    Week 101,079 5,796,858 57.35
    1 Month 59,150 3,505,232 59.26
    6 Month 57,311 3,124,021 54.51

    Biofil Chemicals & Pharmaceuticals Result Highlights

    Biofil Chemicals & Pharmaceuticals Synopsis

    NSE-Medical-Ethical Drugs

    Biofil Chemicals belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 30.04 Cr. and Equity Capital is Rs. 16.27 Cr. for the Year ended 31/03/2023. Biofil Chemicals & Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 04/01/1985 and has its registered office in the State of Madhya Pradesh, India. Company’s Corporate Identification Number(CIN) is L24233MP1985PLC002709 and registration number is 002709.
    Market Cap 85
    Sales 35
    Shares in Float 0.86
    No of funds 4
    Yield
    Book Value 4.92
    U/D Vol ratio 1
    LTDebt / Equity
    Alpha 0.01
    Beta 0.31

    Biofil Chemicals & Pharmaceuticals

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 46.82%46.82%46.82%46.82%
    Foreign Portfolio Investors
    Financial Institutions/ Banks 0.04%0.04%0.04%0.04%
    Individual Investors 37.97%38.1%38.14%38.04%
    Others 15.17%15.04%15%15.1%

    Biofil Chemicals & Pharmaceuticals Management

    Name Designation
    Mr. Ramesh Shah Managing Director
    Mr. Ketan Shah Whole Time Director
    Mr. Romil Shah Non Executive Director
    Mrs. Shaila Jain Independent Director
    Mr. Satish Beohar Independent Director
    Mr. Ashok Kumar Ramawat Independent Director

    Biofil Chemicals & Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Biofil Chemicals & Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2023-11-09 Quarterly Results
    2023-08-14 Quarterly Results
    2023-05-30 Audited Results
    2023-02-14 Quarterly Results
    2022-11-14 Quarterly Results

    Biofil Chemicals & Pharmaceuticals FAQs

    What is Share Price of Biofil Chemicals & Pharmaceuticals ?

    Biofil Chemicals & Pharmaceuticals share price is ₹52 As on 06 December, 2023 | 00:41

    What is the Market Cap of Biofil Chemicals & Pharmaceuticals ?

    The Market Cap of Biofil Chemicals & Pharmaceuticals is ₹85.1 Cr As on 06 December, 2023 | 00:41

    What is the P/E ratio of Biofil Chemicals & Pharmaceuticals ?

    The P/E ratio of Biofil Chemicals & Pharmaceuticals is 125.9 As on 06 December, 2023 | 00:41

    What is the PB ratio of Biofil Chemicals & Pharmaceuticals ?

    The PB ratio of Biofil Chemicals & Pharmaceuticals is 4.9 As on 06 December, 2023 | 00:41

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.